Fewer ocrelizumab dosings for improving quality of life in people with multiple sclerosis

Takeaway

  • Ocrelizumab appears to induce durable relapsing disease inhibition for people with multiple sclerosis (MS), supporting a reduced frequency of dosing.

Why this matters

    Lower frequency administration of ocrelizumab may help reduce serious infections and other risks associated with continuous immunosuppression in people with MS.

Want to read more?

Log in or sign up to access all Neurodiem content.

Already have an account? Log In

International Medical Press is a global provider of independent medical education. Its mission is to provide healthcare professionals with high-quality, trusted medical information with the aim of helping optimize patient care.

No responsibility is assumed by International Medical Press for any injury and/or damage to persons or property through negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein. Because of rapid advances in the medical sciences, International Medical Press recommends that independent verification of diagnoses and drug dosages should be made. The opinions expressed do not reflect those of International Medical Press or the sponsor. International Medical Press assumes no liability for any material contained herein.